2483. Characteristics and Outcomes Over First 12 Months of a Two-Drug Regimen (Dolutegravir/Rilpivirine) for Treatment of HIV-1 in the United States

BACKGROUND: In 2017, the first complete antiretroviral regimen (ART) containing only two drugs, dolutegravir/rilpivirine (DTG/RPV), was approved for treatment of HIV-1 in virologically suppressed (<50 copies/mL) patients on a stable ART regimen for ≥6 months with no history of treatment failure/r...

Descripción completa

Detalles Bibliográficos
Autores principales: Pierone, Gerald, Schulman, Kathy, Fusco, Jennifer S, Vannappagari, Vani, Aboud, Michael, Ragone, Leigh, Fusco, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809477/
http://dx.doi.org/10.1093/ofid/ofz360.2161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809477/
http://dx.doi.org/10.1093/ofid/ofz360.2161

Ejemplares similares